Investors extended their retreat from Introgen Therapeutics Inc. for a third day on Thursday following a major blow from the U.S. Food and Drug Administration. On Tuesday Austin-based Introgen announced the FDA had declined to accept its application to market Advexin, the head and neck cancer drug the company has spent more than a decade developing.
